Table 4.

Aortic distensibility (AD) between baseline and year 1

Comparison		AD (10−3 mm Hg−1) Geometric mean (95% CI), (unadjusted)		Ratio (95% CI), P value
				Unadjusted	Adjusted 1	Adjusted 2
Combined TA1 and TA2 (n=81) Baseline 1 year		3.0 (2.7 to 3.4) 3.6 (3.1 to 4.1)		1.2 (1.1 to 1.3), <0.01	na	na
TA1 at 1 year (all n=40)	TA2 at 1 year (all n=41)	3.8	3.4	0.9 (0.7 to 1.2), 0.49	0.9 (0.7 to 1.2), 0.42	0.9 (0.8 to 1.2), 0.56
Combined TA1 and TA2 at 1 year (non-responders n=38)	Combined TA1 and TA2 at 1 year (responders n=43)	3.5	3.6	1.0 (0.8 to 1.4), 0.87	1.0 (0.8 to 1.2), 0.79	1.0 (0.8 to 1.2), 0.86
TA1 at 1 year (non-responders n=17)	TA1 at 1 year (responders n=23)	3.6	3.9	1.1 (0.7 to 1.6), 0.73	1.0 (0.7 to 1.3), 0.84	1.0 (0.7 to 1.3), 0.82
TA1 at 1 year (responders n=23)	TA2a at 1 year (responders n=13)	3.9	2.8	0.7 (0.4 to 1.2), 0.19	0.8 (0.5 to 1.2), 0.29	0.9 (0.6 to 1.4), 0.56

Differences between groups, either unadjusted, adjusted for baseline AD or (additionally) adjusted for age, sex, systolic blood pressure and pack years smoking (±baseline Disease Activity Score with 28 joint count erythrocyte sedimentation rate (DAS28ESR) as applicable).

Response assumed for patients whose responder status at 48 weeks was unknown.

Adjusted 1, adjusted for baseline AD; Adjusted 2, adjusted for baseline AD, age, sex, systolic BP and pack years smoking (± baseline DAS28ESR as applicable); non-responders, patients with DAS28≥2.6 at 48 weeks; responders, patients with DAS28 <2.6 at 48 weeks; TA1, immediate etanercept (ETN) and methotrexate (MTX) treatment; TA2, first-line MTX ± additional conventional synthetic disease-modifying antirheumatic drug; TA2a, TA2 patients that continued csDMARD and did not escalate to delayed ETN/MTX at week 24.